Want to see JP:4563 full AI Analyst Report?
AnGes (4563) AI Stock Analysis
AnGes
(TSE/TYO:4563)
The low overall score is primarily driven by massive cash burn, severe unprofitability, and a rapidly deteriorating equity base that threatens the company's long-term solvency. Technical indicators display a steep downtrend with strong bearish momentum, while negative valuation metrics further underscore the extreme risk associated with this development-stage biotechnology stock.
AnGes (4563) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 143.66M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.77M
- Price to Earnings (P/E)
- -2.7
- Beta (1Y)
- 0.60
- Revenue Growth
- 35.28%
- EPS Growth
- 90.12%
- Country
- Japan
- Employees
- 56
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
AnGes Business Overview & Revenue Model
Company Description
AnGes, Inc., a biopharmaceutical firm headquartered in Ibaraki, Japan, and established in 1999, focuses on pioneering the research and development of gene-based medical solutions. Its primary therapeutic asset is Hepatocyte Growth Factor (HGF) Plasmi...
How the Company Makes Money
AnGes primarily makes money by monetizing its biotechnology pipeline and approved products through a combination of product-related revenue and collaboration-based income. Revenue can include (1) sales of any commercialized products the company has o...
AnGes Financial Statement Overview
Summary
The company exhibits a high-risk financial profile with severe unprofitability and a massive free cash flow deficit of 5.76 billion. Despite 23% top-line revenue growth and low debt, a drastically depleted equity base (plummeting from 26 billion to 3 billion) raises immediate solvency and dilution concerns.
Income Statement
18Very NegativeBalance Sheet
25NegativeCash Flow
12Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 961.90M | 874.12M | 643.00M | 152.99M | 67.06M | 64.15M |
| Gross Profit | 398.00M | 320.38M | 247.00M | 19.45M | -26.83M | 7.43M |
| EBITDA | -5.51B | -5.09B | -5.74B | -8.86B | -13.41B | -13.21B |
| Net Income | -3.87B | -5.12B | -28.13B | -7.44B | -14.71B | -13.68B |
Balance Sheet | ||||||
| Total Assets | 3.66B | 5.41B | 4.67B | 28.89B | 38.82B | 45.46B |
| Cash, Cash Equivalents and Short-Term Investments | 296.72M | 1.88B | 1.71B | 4.16B | 11.04B | 17.90B |
| Total Debt | 723.78M | 54.37M | 272.45M | 362.68M | 1.16B | 0 |
| Total Liabilities | 3.45B | 2.33B | 2.51B | 2.79B | 8.40B | 6.82B |
| Stockholders Equity | 205.68M | 3.08B | 2.16B | 26.10B | 30.43B | 38.63B |
Cash Flow | ||||||
| Free Cash Flow | -1.38B | -5.76B | -6.69B | -8.84B | -11.23B | -11.46B |
| Operating Cash Flow | -1.38B | -5.75B | -6.61B | -8.74B | -11.21B | -11.38B |
| Investing Cash Flow | -80.00K | 18.48M | -130.80M | -356.65M | -97.14M | -154.87M |
| Financing Cash Flow | 567.54M | 5.90B | 4.20B | 2.04B | 3.57B | 17.38B |
AnGes Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4563, the sentiment is Negative. The current price of 26.00 is below the 20-day moving average (MA) of 30.60, below the 50-day MA of 34.84, and below the 200-day MA of 48.78, indicating a bearish trend. The MACD of -2.46 indicates Positive momentum. The RSI at 22.27 is Positive, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4563.
AnGes Peers Comparison
Overall Rating
JP:456567Neutral
JP:458854Neutral
JP:459348Neutral
JP:777442Neutral- JP:456339Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4565 | 67Neutral | JPY 146.80B | -28.89 | -8.51% | ― | 23.72% | 12.48% |
| JP:4588 | 54Neutral | JPY 233.66B | -144.29 | ― | ― | 1662.38% | 42.86% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4593 | 48Neutral | JPY 35.38B | 50.40 | ― | ― | -47.32% | ― |
| JP:7774 | 42Neutral | JPY 24.16B | -56.73 | ― | ― | 17.05% | 10.47% |
| JP:4563 | 39Underperform | JPY 11.13B | -2.73 | -163.39% | ― | 35.28% | 90.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4563 | AnGes | 26.00 | -53.00 | -67.09% | |
| JP:4565 | Sosei Group Corporation | 1729.00 | 948.00 | 121.38% | |
| JP:4588 | Oncolys BioPharma, Inc. | 7550.00 | 6699.00 | 787.19% | |
| JP:4593 | Healios KK | 245.00 | -222.00 | -47.54% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 601.00 | 138.00 | 29.81% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 12, 2026